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The cytotoxic effects of anticancer immune cells are mediated by perforin/granzyme-B, Fas ligand and tumour necrosis factor-related
apoptosis-inducing ligand (TRAIL), and therefore depend on intact apoptotic responses in target tumour cells. As killing by all three of
these mechanisms is blocked by the frequently overexpressed antiapoptotic oncoprotein Bcl-2, we hypothesised that coexposure to
a Bcl-2 inhibitor might enhance anticancer immune responses. We evaluated this in U937 lymphoma cells, and A02 melanoma cells,
which both show strong Bcl-2 expression. Va24
þ Vb11
þ natural killer T (NKT) cells expanded from peripheral blood of normal
donors (n¼3) were coincubated with PKH26-labelled U937 cells, and cytotoxicity was determined by flow cytometry after annexin-
V-FITC and 7-AAD staining. In all cases, addition of the HA14-1 small-molecule Bcl-2 inhibitor to the cocultures significantly increased
apoptosis in the target U937 cells. Using a similar assay, killing of A02 cells by the cytotoxic T-lymphocyte clone 1H3 was shown to be
amplified by coexposure to the potent small-molecule Bcl-2 inhibitor ABT-737. Experiments with immune effectors preincubated
with concanamycin-A suggested that sensitisation to perforin/granzyme-B may underlie enhanced target-cell killing observed in the
presence of Bcl-2 inhibitors. We conclude that immune destruction of malignant cells can be amplified by molecular interventions that
overcome Bcl-2-mediated resistance to apoptosis.
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Anticancer agents such as radiation therapy and chemotherapy
kill tumour cells largely by inducing programmed cell death or
apoptosis. This is also true for anticancer immune responses,
where apoptosis is triggered by the mechanisms including
perforin/granzyme-B, Fas ligand (FasL) and tumour necrosis
factor-related apoptosis-inducing ligand (TRAIL). However,
tumours frequently overexpress genes that inhibit apoptosis and
which therefore contribute to treatment resistance (Cory et al,
1999). The Bcl-2 family of antiapoptosis mitochondrial proteins
(which also includes Bcl-xL and Mcl-1) is an important example of
this. These proteins are potent inhibitors of cell death, and high
expression levels are observed in many cancers (Adams and Cory,
1998; Reed, 1999). Bcl-2 itself is highly expressed in the majority of
cases of acute leukaemia, approximately 50% of diffuse large B-cell
lymphomas and up to 90% of malignant melanomas (Banker et al,
1997; Jansen et al, 1998; Campos et al, 1999; Skinnider et al, 1999).
Forced expression of Bcl-2 results in resistance to a variety of
proapoptotic stimuli, including growth factor withdrawal, cyto-
toxic chemotherapy and radiation, and there is some evidence that
Bcl-2 also promotes resistance to anticancer immune responses.
For example, transfection-mediated overexpression of Bcl-2
rendered Jurkat leukaemia cells refractory to killing by a cytotoxic
T-cell clone (Torigoe et al, 1994). In other studies, enforced Bcl-2
expression was shown to inhibit several key mechanisms of
immune killing, including those initiated by granzyme-B, FasL and
TRAIL (Pinkoski et al, 2001; Raisova et al, 2001; Fulda et al, 2002;
Guseva et al, 2002; Velthuis et al, 2002).
Interfering with the expression or function of Bcl-2 might be an
effective anticancer strategy. Antisense oligonucleotides that
decrease Bcl-2 expression caused direct tumour suppression and
increased sensitivity to cytotoxic chemotherapy in preclinical
models (Cotter et al, 1994; Jansen et al, 1998). However, Bcl-2
antisense therapy had limited activity when tested in clinical trials,
potentially owing to poor access to the intracellular compartment
and inadequate reduction in Bcl-2 expression levels (Waters et al,
2000; Yuen and Sikic, 2000; Morris et al, 2002). More recently,
small molecules that target the BH3-domain-binding site of Bcl-2
have been developed as Bcl-2 inhibitors (Wang et al, 2000;
Oltersdorf et al, 2005). It is hypothesised that these agents displace
proapoptotic BH3-only proteins (e.g., Bid and Bim) from their
binding groove on Bcl-2, thus promoting interaction with Bax
and Bak, and transduction of an apoptotic signal (Oltersdorf
et al, 2005). One of these compounds – ethyl 2-amino-6-
bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxy-
late (designated HA14-1) – directly triggered apoptosis in Bcl-2-
expressing leukaemia and lymphoma cell lines, and also enhanced
the cytotoxicity of the antileukaemia drug cytarabine (Wang et al,
2000; Lickliter et al, 2003). A more-recently developed compound,
ABT-737, bound to Bcl-2 and Bcl-xL with extremely high affinity Revised 14 December 2006; accepted 19 December 2006
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s(inhibitory constant Kip1n M), and exhibited significant in vitro
and in vivo activity in preclinical models of follicular lymphoma
and small-cell lung cancer (Oltersdorf et al, 2005). In addition,
ABT-737-induced apoptosis in primary patient-derived samples of
follicular lymphoma cells and chronic lymphocytic leukaemia cells.
Inhibition of Bcl-2 may be of particular benefit in combination
with other strategies that promote apoptosis of malignant cells. As
Bcl-2 overexpression may protect malignant cells from antitumour
immune responses, we investigated whether coexposure to both
Bcl-2 inhibitor and activated immune cells could increase tumour-
cell killing. This hypothesis was examined in two models of
anticancer immunotherapy. The first utilised human Va24
þ
Vb11
þ T-cell receptor (TCR) expressing natural killer T cells
(NKT cells) as the immune effector cells (Nieda et al, 1999).
Natural killer T cells have been shown to exert significant in vitro
and in vivo antitumour activity against a variety of solid
malignancies and myeloid leukaemia (Kikuchi et al, 2001; Nieda
et al, 2001). Relevant to their practical application in human
immune therapies, they can be potently activated by agents such as
a-galactosylceramide (KRN7000). We chose the U937 lymphoma
cell line as the NKT-cell target (Nicol et al, 2000; Takahashi et al,
2000) because U937 cells express high levels of antiapoptotic Bcl-2
(Lickliter et al, 2003). The second model is also relevant to clinical
immunotherapy, with the use of A02 human melanoma cells as the
target and a Melan-A/MART-1-specific cytotoxic T-lymphocyte
(CTL) clone as effector cells. Like U937 cells, A02 cells strongly
express Bcl-2 and were therefore suitable for investigating the
combined effects of immune attack and exposure to a Bcl-2
inhibitor.
MATERIALS AND METHODS
NKT cells
Peripheral blood mononuclear cells (PBMC) were separated from
peripheral blood of healthy adult volunteers (n¼3) by density
centifugation over Ficoll-Paque PLUS (Amersham Biosciences,
Uppsala, Sweden). Informed consent was obtained from donors
before blood collection, and the research was approved by the
Human Research Ethics Committees of the Royal Brisbane and
Women’s Hospital, and Queensland Institute of Medical Research.
Following isolation, PBMC were resuspended in AIM-V medium
(Gibco BRL, Melbourne, Australia) supplemented with 10% foetal
calf serum (Gibco BRL), penicillin/streptomycin, 100ngml
 1
KRN7000 (Kirin Brewery, Japan) and 10Uml
 1 interleukin-2
(IL-2; R&D Systems, Sydney, Australia), and incubated at 371Ci na
5% CO2 atmosphere. After 7 days, the activated and expanded NKT
cells were positively selected using an anti-Va24 monoclonal
antibody (Beckman Coulter, Sydney, Australia) and magnetic
beads (miniMACS system, Miltenyi Biotec, Sydney, Australia). The
frequency of NKT cells at specific points during their expansion
and purification was assessed with an XL-MCL flow cytometer
(Beckman Coulter) after staining with anti-Va24-fluorescein
isothiocyanate (FITC), anti-Vb11-phycoerythrin (PE) and anti-
CD3-phycocyanin 5 (PC5) antibodies (Beckman Coulter). Results
were analysed with EXPO32 software (Beckman Coulter).
Bcl-2 expression in target cells
The A02 melanoma cell line was derived at the Queensland
Institute of Medical Research from a mechanically disaggregated
fresh surgical melanoma specimen taken from an HLA-A0201
positive patient. A02 cells and U937 lymphoma cells were grown at
371C in a 5% CO2 atmosphere using RPMI 1640 medium
supplemented with 10% foetal calf serum, penicillin and strepto-
mycin. To determine Bcl-2 expression in the U937 cells, aliquots of
5 10
5 cells were fixed and permeabilised using the IntraPrep kit
(Immunotech, France) according to the manufacturer’s instruc-
tions. Cells were then stained with 5ml of FITC-conjugated anti-
Bcl-2 monoclonal antibody (clone 124; Dako, Carpinteria, CA,
USA) or an IgG1 isotype control (BD Biosciences, San Jose, CA,
USA), and examined with an XL-MCL flow cytometer. Results were
analysed using Summit version 3.1 software (Cytomation Inc. Fort
Collins, CO, USA). Bcl-2 expression in the A02 cells was
determined by Western blotting. Cells were resuspended in lysis
buffer (50mM Tris pH 7.6, 250mM NaCl, 5mM EDTA pH 8, 50mM
NaF and 50mM PMSF) and centrifuged. The supernatant was then
collected and 100mg of protein was separated by SDS-polyacryla-
mide gel electrophoresis and electroblotted onto a PVDF
membrane (Bio-Rad). The membrane was incubated with anti-
Bcl-2 monoclonal antibody (clone 124, Dako) at a dilution of
1:200, followed by a secondary horseradish peroxidase-conjugated
rabbit anti-mouse IgG antibody (Dako) at a dilution of 1:5000.
Binding of antibodies was visualised by enhanced chemilumines-
cence (ECL; Amersham Biosciences). To confirm even loading of
the gel lanes with protein, the membrane was re-probed with an
anti-b-actin antibody (clone AC-15; Sigma Aldrich, Sydney, Australia).
Preparation of compounds
The HA14-1 small-molecule inhibitor of Bcl-2 was purchased from
Maybridge (Tintagel, UK; product code BTB02933). The com-
pound was dissolved in dimethyl sulphoxide (DMSO), diluted in
cell-culture medium to a concentration of 500mM and stored at
 701C. A fresh aliquot was thawed and used immediately in each
experiment. ABT-737 (a gift from Abbott Laboratories, Abbott
Park, IL, USA) was dissolved in DMSO and stored at  201C.
Cytotoxicity assays
Purified NKT cells were seeded into round bottom 96-well plates at
a density of 2 10
5cellswell
 1 in a final volume of 200ml of AIM-V
medium/10% foetal calf serum. U937 cells were washed in serum-
free medium and stained with the membrane dye PKH26 (Sigma),
according to the manufacturer’s instructions. PKH26-labelled
U937 cells were then added to wells containing NKT cells for an
effector:target (E:T) ratio of 20:1 (donor 1) or 10:1 (donors 2 and
3), and coincubated at 371Ci n5 %C O 2 for a total of 4h. After the
initial 1h of incubation, either 25mM of the HA14-1 Bcl-2 inhibitor
or DMSO vehicle alone was added to the coculture wells and
to control wells containing U937 cells alone. To evaluate for
apoptosis, cells were washed in annexin–V-binding buffer (10mM
HEPES pH 7.4, 140mM NaCl and 2.5mM CaCl2), and stained with
5ml of annexin-V-FITC (BD Biosciences) and 10ml (0.5mg) of 7-
amino-actinomycin D (7-AAD; BD Pharmingen). A minimum of
10000 events per sample was then acquired on an XL-MCL flow
cytometer and results were analysed using EXPO32 or Summit
version 3.1 software. U937-cell viability was defined as the
percentage of PKH26
þ cells that was negative for annexin-V.
The 1H3 antimelanoma CTL clone was derived from PBMC
isolated from an HLA-A0201 positive melanoma patient and
recognises the Melan-A/MART-1 melanoma antigen. Cryopre-
served 1H3 cells were thawed and stimulated at 20000cellswell
 1
in a U-bottom 96-well plate containing irradiated (3000rad)
feeder cells (1 10
5 allogenic PBMC and 2 10
4cellswell
 1 BLCL).
Stimulatory medium consisted of RPMI 1640 containing 5%
pooled human sera, 100Uml
 1 IL-2 and 1mgml
 1 phytohemag-
glutinin-L (PHA-L). After 7 days, half of the medium volume was
replaced with medium containing 5% pooled human sera and
100Uml
 1 IL-2 without PHA-L. For all experiments, clones were
used at least 7 days after the start of expansion. A02 melanoma
cells were de-adhered from tissue culture flasks using trypsin
without EDTA and stained with PKH26 dye (Sigma), according to
the manufacturer’s instructions. The labelled A02 cells were then
added to U-bottom 96-well plate containing 1H3 cells to achieve an
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sE:T ratio of 0.2:1, and the cocultures were incubated at 371Ci n
5% CO2 for a total of 4 or 8h. After the initial 1h of incubation,
either 1mM of ABT-737 or the corresponding amount of DMSO
vehicle alone was added to the coculture wells, and to control wells
containing A02 cells alone. Apoptosis was subsequently evaluated
by annexin-V and 7-AAD staining (as described above), followed
by analysis with a FACSCalibur flow cytometer and CellQuest Pro
version 5.2 software (BD Biosciences). At least 10000 events were
acquired per sample.
Inhibition of perforin/granzyme-B
To investigate the role of the perforin/granzyme-B pathway,
immune effector cells were preincubated for 2h with the perforin
inhibitor concanamycin-A (Sigma) at 100nM (NKT cells) or
1000nM (1H3 cells), or with the corresponding amount of DMSO
vehicle alone (Kataoka et al, 1996). The effector cells were then
washed twice with phosphate-buffered saline and used in
cytotoxicity assays similar to those described above.
RESULTS
Expansion and purification of NKT cells
Freshly isolated PBMC from all normal donors studied contained
detectable numbers of NKT cells (Figure 1; Table 1). These
numbers markedly increased following 7 days of stimulation with
IL-2 and KRN7000, resulting in NKT-cell frequencies of 18–36% of
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Figure 1 Expansion and purification of NKT cells from normal donor PBMNC. Typical results before expansion (A), after 7 days of expansion culture (B)
and following magnetic separation of Va24
þ cells (C) are shown. Cells were stained with anti-Va24-FITC, anti-Vb11-PE and anti-CD3-PC5 antibodies, and
then analysed by flow cytometry. Right panels were gated on the PBMNC region defined in the left panels, and Va24
þ Vb11
þ NKT cells were counted in
the region shown. Abbreviations: FSC, forward scatter; SSC, side scatter; RBCþdebris, region-containing erythrocytes and debris; Neuts, neutrophils;
Monos, monocytes; Lymphs, lymphocytes.
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smononuclear cells. Following magnetic separation, populations of
Va24
þ Vb11
þ NKT cells that were 79–96% pure were obtained.
Consistent with an NKT-cell phenotype, these cells were also
positive for CD3 (data not shown).
Cytotoxic effects of combined NKT cells and HA14-1 on
U937 lymphoma cells
Bcl-2-expressing U937 lymphoma cells (Figure 2) were coincu-
bated with purified NKT cells from each normal donor. To test the
effect of suppressing Bcl-2 function on the susceptibility of U937
cells to NKT-cell cytotoxicity, cocultures were supplemented either
with the HA14-1 small-molecule Bcl-2 inhibitor or with vehicle
alone. Viability of the U937 target cells was then evaluated with a
well-established flow-cytometry technique (Fischer et al, 2002; Lin
et al, 2004), as shown in Figure 3. This involved utilising the
PKH26 fluorescent membrane dye to distinguish U937 cells from
NKT effector cells and FITC-conjugated annexin-V to stain dying
cells. Therefore, viable and dying U937 cells were identified as
PKH26
þ/annexin-V
  and PKH26
þ/annexin-V
þ populations,
respectively. Figure 3 illustrates that HA14-1 on its own triggered
only a low level of cell death at the concentration used in these
experiments. Natural killer T cells in the absence of HA14-1 were
cytotoxic; however, combined exposure to both NKT cells and the
Bcl-2 inhibitor resulted in a significant amplification of cytotoxi-
city with a corresponding marked increase in annexin-V
þ U937
cells. As shown in Figure 4, the enhanced cytotoxicity induced by
coexposure to HA14-1 was observed in experiments with NKT cells
isolated from all three normal donors tested. The mean U937-cell
viability in the cocultures decreased from 44.5 to 13.7% (donor 1),
59.1 to 24.6% (donor 2) and 76.6 to 33.9% (donor 3) with the
addition of HA14-1. Compared to the effects of NKT cells alone,
combination with the Bcl-2 inhibitor therefore reduced target-cell
viability by an additional 56–69%. Importantly, since HA14-1 on
its own reduced the viability of U937 cells by only 9–18%, our
results indicate that coexposure to NKT cells and HA14-1
enhanced target-cell destruction in a synergistic fashion.
Inhibition of Bcl-2 with HA14-1 should induce apoptosis rather
than primary necrosis. We therefore investigated the mode of
U937-cell death in the cocultures by analysing the pattern of
7-AAD staining in PKH26
þ/annexin-V
þ cells. As described
previously (Philpott et al, 1996), necrotic cells stain brightly for
7-AAD, whereas apoptotic cells become dimly positive. Figure 5
shows results from a typical coculture experiment after gating on
the PKH26
þ population. Exposure to NKT cells in the absence of
HA14-1 resulted in annexin-V
þ U937 cells that were 7-AAD
negative, 7-AAD dim and 7-AAD bright. Significantly, coexposure
to HA14-1 caused a marked increase in the 7-AAD-dim
subpopulation, indicating that the increase in U937-cell death
was predominantly owing to apoptosis.
CTL killing of melanoma cells is amplified by the ABT-737
Bcl-2 inhibitor
Figure 6 shows that the A02 melanoma cell line strongly expresses
antiapoptotic Bcl-2. The expression level is significantly higher
than in K562 cells and is comparable to that in the LK63 acute
lymphoblastic leukaemia line, which expresses high levels of the
Bcl-2 oncoprotein that influence its survival (Lickliter et al, 2003).
We investigated whether inhibiting Bcl-2 in A02 cells with the
potent small-molecule inhibitor ABT-737 would sensitise them to
destruction by a Melan-A/MART-1-specific antimelanoma CTL
line (Figure 7). Effector 1H3 cells were coincubated with target A02
cells at a low E:T ratio (0.2:1), to better simulate the conditions
encountered in vivo in clinical immunotherapy. Target cells were
again labelled with PKH26 and wells were supplemented with
either ABT-737 at 1mM or vehicle alone after the initial 1h of
coculture. A proportion of the PKH26
þ target cells (o20%) was
positive for 7-AAD; however, this was not significantly different
between control wells containing A02 cells alone and coculture
wells supplemented with vehicle alone or ABT-737 (data not
shown). This population likely represents A02 cells that sustained
mechanical damage at baseline when de-adhered from tissue
culture flasks. Flow-cytometry analysis plots were therefore gated
on PKH26
þ events that were negative for 7-AAD, so as to exclude
this background cell death. The proportion of annexin-V
þ cells in
the gated population (indicated as percentages in Figure 7) is a
measure of the specific killing of A02 cells by the CTL clone and/or
ABT-737. Typical results from one of the three independent
experiments are shown in Figure 7. This indicates that either 1H3
antimelanoma T cells or the ABT-737 Bcl-2 inhibitor caused
significant destruction of the A02 cells on their own. In contrast,
when A02 cells were exposed to both CTL and ABT-737, there was
a substantial amplification of target-cell killing. In the experiment
shown, CTL alone triggered a 9% increase in A02 cell death over
baseline, whereas CTL and ABT-737 induced a 36% increase. As
ABT-737 alone was associated with only a 4% increase in
cytotoxicity, the combined treatment resulted in supraadditive
destruction of the melanoma cells. Importantly, the increase in A02
cell death was due to an increase in the annexin-V
þ 7-AAD
 
subpopulation and therefore specifically to an increase in
apoptosis.
Role of perforin/granzyme-B
We next investigated whether blocking the perforin/granzyme-B
effector pathway of immune cells would affect the enhanced target-
cell killing associated with coexposure to a Bcl-2 inhibitor. NKT
cells from donor 2 were preincubated with either the perforin
inhibitor concanamycin-A or vehicle alone, before establishing
Table 1 NKT-cell frequencies in samples from three normal donors,
evaluated using the method shown in Figure
Day 0 Day 7 Postseparation
Donor 1 0.1 36.1 95.7
Donor 2 0.5 17.9 94.5
Donor 3 0.1 18.9 79.0
Results before expansion (Day 0), after 7 days of expansion culture (Day 7) and after
magnetic separation of Va24
+ cells (postseparation) are shown, expressed as a
percentage of total mononuclear cells.
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Figure 2 Bcl-2 expression in U937 cells. The histogram plot shows
flow-cytometry results after intracellular staining of U937 cells with FITC-
conjugated anti-Bcl-2 antibody (gray plot) or isotype control antibody
(open plot).
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Figure 3 Effect of the HA14-1 Bcl-2 inhibitor on cytotoxicity induced in U937 lymphoma cells by NKT cells. PKH26-labelled U937 cells were coincubated
with purified NKT cells at a 10:1 effector:target ratio, either with HA14-1 (D) or with vehicle alone (C). U937 cells incubated without NKT cells were also
exposed to HA14-1 (B) or vehicle only (A). After 4h, the cells were stained with annexin-V-FITC and 7-AAD, and then analysed by flow cytometry. The
proportion of U937 target cells undergoing cell death was determined by first gating on PKH26
þ cells (region R1, left panels) and then enumerating
annexin-V
þ events (region R2, right panels) in the gated population.
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scocultures with U937 target cells. Typical results from one of two
independent experiments are shown in Figure 8 and reveal that
inhibition of perforin did not significantly alter NKT-cell killing
of U937 cells in the absence of HA14-1. This suggests that the
perforin/granzyme-B system did not significantly contribute to
the baseline cytotoxicity of NKT cells from this donor against the
U937-cell targets. In contrast, the increase in U937-cell death
induced by coexposure to HA14-1 was almost completely blocked
by preincubation of the NKT cells with concanamycin-A. These
results suggest that the perforin/granzyme-B pathway plays an
essential role in the amplification of cytotoxicity against U937 cells
mediated by HA14-1, at least in the case of NKT cells isolated from
donor 2. We also investigated the role of perforin and granzyme-B
in the augmentation of 1H3-cell cytotoxicity against A02
melanoma cells associated with coexposure to the ABT-737 Bcl-2
inhibitor. In this model, inhibition of perforin with concanamycin-
A almost completely abolished CTL cytotoxicity, both in the
presence and absence of ABT-737 (data not shown). This indicates
that 1H3 cells killed their A02 targets almost exclusively via the
perforin/granzyme-B pathway. Consequently, the significant in-
crease in killing of A02 cells observed with ABT-737 coexposure
potentially reflects a heightened susceptibility to apoptosis
induction by granzyme-B.
DISCUSSION
We investigated the effects of inhibiting the Bcl-2 antiapoptosis
oncoprotein on the susceptibility of Bcl-2-overexpressing tumour
cells to cytotoxic immune cells. NKT cells derived from three
normal donors all showed markedly increased cytotoxicity against
Bcl-2-positive U937 lymphoma cells when combined with the
HA14-1 small-molecule inhibitor of Bcl-2. In addition, a CTL
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Figure 4 Cytotoxicity of NKT cells from three normal donors in
combination with HA14-1, determined as shown in Figure 3. Bars represent
mean U937-cell viability in triplicate assays, normalised to the viability of
control cells. Results following exposure to HA14-1 alone (HA14-1), NKT
cells plus DMSO vehicle (NKT) and NKT cells plus HA14-1 (NKTþHA14-
1) are shown. Error bars indicate the s.d.
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Figure 5 Analysis of 7-AAD staining of U937 target cells. Cocultures of NKT cells and PKH26-labelled U937 cells were stained with annexin-V-FITC and
7-AAD, and then analysed by flow cytometry. Plots gated on PKH26
þ cells are shown for cocultures supplemented with vehicle only (NKT alone) or with
HA14-1 (NKTþHA14-1).
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Figure 6 Western blot showing expression of Bcl-2 in A02 melanoma
cells compared with that in cells with low expression (K562) and high
expression (LK63) levels. The blot was probed with an anti-Bcl-2
monoclonal antibody and subsequently with an anti-b-actin antibody, as a
loading control.
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santimelanoma clone specific for Melan-A/MART-1 revealed
significantly more killing of Bcl-2-overexpressing A02 melanoma
cells in the presence of the potent Bcl-2 inhibitor ABT-737.
Consistent with the cellular physiology of Bcl-2 inhibition, target
tumour cells were predominantly induced to undergo apoptosis
by combined treatment with immune effector cells and a Bcl-2
inhibitor. Our findings therefore support the hypothesis that Bcl-2
expression in the target U937 and A02 cells suppressed the
proapoptotic effects of antitumour immune cells, and that
inhibition of Bcl-2 can remove this suppression and allow
apoptosis of the tumour cells to proceed.
The perforin/granzyme-B system is an important mechanism of
CTL-mediated tumour cell destruction and also contributes to
NKT-cell cytotoxicity against U937 cells (Takahashi et al, 2000;
Voskoboinik and Trapani, 2006). Moreover, Bcl-2 expression can
block apoptosis induced by granzyme-B (Pinkoski et al, 2001). We
therefore investigated whether sensitization to the effects of the
perforin/granzyme-B system could explain the increased target cell
apoptosis observed with coexposure to a Bcl-2 inhibitor. In the
case of NKT cells, pretreatment with the perforin inhibitor
concanamycin-A resulted in no reduction in the killing of U937
cells in the absence of HA14-1, but caused almost complete
abrogation of HA14-1-mediated cytotoxicity amplification. One
explanation for these results is that Bcl-2 overexpression in the
U937 cells caused essentially complete suppression of granzyme-B-
induced apoptosis. This was reversed by HA14-1 binding to Bcl-2,
resulting in increased killing of U937 cells via the perforin/
granzyme-B mechanism. As perforin inhibition by concanamycin-
A abrogated almost all of this increase, it follows that the perforin/
granzyme-B system was the predominant pathway affected by the
Bcl-2 inhibitor in the cells tested. In the case of 1H3 T-cells,
destruction of A02 melanoma cells was mediated almost exclu-
sively via the perforin/granzyme-B system, either in the presence
or absence of the Bcl-2 inhibitor. The marked increase in
cytotoxicity associated with coexposure to ABT-737 in this model
is therefore likely due to sensitization to the pro-apoptotic effects
of perforin/granzyme-B. From a mechanistic standpoint, it is
significant that the pro-apoptotic BH3-only protein Bid is cleaved
to its active form by granzyme-B, allowing it to trigger
cytochrome-c release from mitochondria, caspase activation and
apoptosis (Ida et al, 2003). Bcl-2 expressed by tumour cells could
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Figure 7 Destruction of A02 melanoma cells by an activated CTL clone
is enhanced by coexposure to the small-molecule Bcl-2 inhibitor ABT-737.
PKH26-labelled A02 cells were coincubated with the Melan-A/MART-1
specific T-cell clone 1H3 at an E:T ratio of 0.2:1. After 1h, either
1mMABT-737 (D) or vehicle alone (C) was added to the cocultures.
Control wells with A02 cells alone were also exposed to 1mMABT-737 (B)
or vehicle only (A). After a total of 4h, the A02 target cells were evaluated
for cell death by staining with annexin-V-FITC and 7-AAD, followed by flow
cytometry analysis. The histograms shown were gated on events positive
for PKH26 and negative for 7-AAD, to exclude non-target cells and
necrotic target cells. The percentages shown below the markers represent
the percentage of annexin-V
þ events and therefore enumerate apoptotic
A02 cells.
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Figure 8 Effect of inhibiting the perforin/granzyme-B pathway. The
cytotoxicity of NKT cells preincubated with either concanamycin-A or
control medium was assessed in combination with HA14-1 or vehicle only,
using the method shown in Figure 3. Bars indicate mean U937-cell viability
in triplicate assays and error bars the s.d.
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apoptosis in the face of immune cell-derived granzyme-B.
However, coexposure to BH3 mimetic compounds (such as
HA14-1 and ABT-737) could potentially displace activated Bid
from Bcl-2, and thus promote cell death.
Our results suggest that combining a Bcl-2 inhibitor with clinical
immunotherapy may result in enhanced anticancer efficacy.
Moreover, Bcl-2 inhibitors may be especially useful in tumours
where the perforin/granzyme-B system is the main functional
pathway available for target cell killing. For example, FasL and
TRAIL do not effectively signal apoptosis in some tumour cells
(Mace et al, 2006), and therefore targeting the perforin/granzyme-
B mechanism may be essential to immunological antitumour
activity in these cases. Effective small-molecule inhibitors of Bcl-2
and related antiapoptosis proteins are now in late preclinical and
early clinical development. For example, a phase I study in solid
tumours of GX15-07 (a pan-Bcl-2 family inhibitor developed
by Gemin X Biotechnologies, Montreal, Canada) has already
commenced. The Abbott Laboratories compound ABT-737 has
shown considerable promise in preclinical studies, and clinical
trials of this (or related) molecules may follow (Oltersdorf et al,
2005). Consequently, clinical trials of Bcl-2 inhibitory drugs in
combination with anticancer immunotherapy may soon be
feasible. Bcl-2 inhibition, however, might also induce apoptosis
in activated immune cells, and this could limit its application in
immunotherapy strategies involving the in vivo activation of
antitumour lymphocytes. It is therefore possible that Bcl-2
inhibitors will be most useful in conjunction with adoptive
immunotherapy. For example, infusions of immune cells activated
by cytokines ex vivo could be combined with a Bcl-2 inhibitor
in a temporal sequence similar to that used in the current
in vitro study.
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